<?xml version='1.0' encoding='utf-8'?>
<document id="24729909"><sentence text="Metabotropic glutamate receptor 5 negative modulation in phase I clinical trial: potential impact of circadian rhythm on the neuropsychiatric adverse reactions-do hallucinations matter?"><entity charOffset="13-22" id="DDI-PubMed.24729909.s1.e0" text="glutamate" /></sentence><sentence text="Metabotropic Glutamate Receptor 5 (mGluR5) negative allosteric modulators (NAMs) may play a role in some psychiatric disorders such as anxiety and depression"><entity charOffset="13-22" id="DDI-PubMed.24729909.s2.e0" text="Glutamate" /></sentence><sentence text=" The pharmacokinetic profile and pharmacodynamics effects of mGluR5-NAMs have been previously reported"><entity charOffset="61-72" id="DDI-PubMed.24729909.s3.e0" text="mGluR5-NAMs" /></sentence><sentence text=" We performed a post hoc analysis of pharmacological and clinical data obtained from 18 young healthy female subjects who received a mGluR5-NAM in the context of a phase I drug-drug interaction study between a mGluR5 NAM and a monophasic oral contraceptive" /><sentence text=" mGluR5-NAM was administered in an escalating bidaily dose level design" /><sentence text=" There was no interaction between the OC and mGluR5-NAM" /><sentence text=" Higher morning mGluR5-NAM plasma concentrations were found compared to evening concentrations" /><sentence text=" Most of the observed clinically significant neuropsychiatric adverse reactions occurred nocturnally and included visual (pseudo) hallucinations, insomnia accompanied by secondary behavioural disorders, and cognitive dysfunction symptoms of sufficient severity to interfere with daily functioning" /><sentence text=" Circadian rhythm-related physiological variations in drug absorption and disposition may explain this pharmacokinetics-pharmacodynamics apparently disproportionate relationship" /><sentence text=" We suggest that clinical trials evaluating basic pharmacokinetic properties of psychiatric medications consider potential drug's chronopharmacokinetics" /><sentence text=" This may assist with dose optimization and minimize serious neuropsychiatric adverse reactions in the vulnerable psychiatric patient" /><sentence text=" " /></document>